Dr. Oguchi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
955 Town Center Dr
Suite 100
Orange City, FL 32763Phone+1 386-228-0661Fax+1 386-228-0662
Education & Training
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Infectious Disease, 2002 - 2004
Ascension Illinois/Saint Joseph (Chicago)Residency, Internal Medicine, 1999 - 2002
University of Nigeria Faculty of MedicineClass of 1988
Certifications & Licensure
FL State Medical License 2003 - 2026
IL State Medical License 1999 - 2002- American Board of Internal Medicine Infectious Disease
Clinical Trials
- 12-Week Study of Plecanatide for CIC (The CIC3 Study) Start of enrollment: 2013 Nov 01
Publications & Presentations
PubMed
- 89 citationsEfficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically su...Eric S. Daar, Edwin DeJesus, Peter Ruane, Gordon Crofoot, Godson Oguchi
The Lancet. HIV. 2018-07-01 - 492 citationsAll-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III StudyDavid R. Nelson, James N. Cooper, Jacob Lalezari, Eric Lawitz, Paul J. Pockros
Hepatology. 2015-04-01
Authored Content
- Early Remdesivir to Prevent Progression to Severe Covid -19 in OutpatientsDecember 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
